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Abstract: Treatment of lung cancer depends on the stage of the tumor and the histological type. In 
recent years, the histological confirmation of lung non-small-cell lung cancer has become crucial 
since the availability of selective target therapeutic approaches. The aim of the study was to develop 
a validated procedure to estimate the incidence and prevalence of non-small-cell and small-cell lung 
cancer from healthcare administrative data. A latent class model for categorical variables was ap-
plied. The following observed variables were included in the analysis: ICD-9-CM codes in the Hos-
pital Discharge Registry, ATC codes of medications dispensed present in the Drugs Prescriptions 
Registry, and the procedure codes in the Outpatient Registry. The proportion of non-small-cell lung 
cancer diagnoses was estimated to be 85% of the total number of lung cancer on the cohort of inci-
dent cases and 89% on the cohort of prevalent cases. External validation on a cohort of 107 patients 
with a lung cancer diagnosis and histological confirmation showed a sensitivity of 95.6% (95%CI: 
89–98.8%) and specificity of 94.1% (95%CI: 71.3–99.9%). The procedure is an easy-to-use tool to de-
sign subpopulation-based studies on lung cancer and to better plan resource allocation, which is 
important since the introduction of new targeted therapies in non-small-cell lung carcinoma. 
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1. Introduction 
The Italian Association of Medical Oncology estimated 42,500 new lung cancer cases 
in Italy in 2019. Of them, 29,500 (69%) occurred in men and 13,000 (31%) occurred in 
women. The lifetime odds of developing lung cancer are 1:11 for men and 1:39 for women 
[1]. According to the WHO classification, more than 95% of lung cancers can be traced 
back to two main histotypes: non-small-cell lung cancer (NSCLC) and small-cell carci-
noma (SCLC) or microcytoma [2]. In turn, NSCLC comprises three main subtypes: squa-
mous cell carcinoma, adenocarcinoma, and large cell carcinoma. 
Treatment of lung cancer depends on the histological type and the stage of the tumor, 
and in recent years, the histological confirmation of NSCLC has become crucial since the 
availability of selective target therapeutic approaches [3]. Thus, it is important to estimate 
the incidence and prevalence of histological lung cancer subtypes for better planning the 
resource allocation needed for the management of the disease [4,5]. 
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In Italy, about 75% of the lung cancer cases collected by the cancer registries have 
histological confirmation (data referring to years 2010–2014): Of these, 40% are adenocar-
cinomas, 21% are squamous carcinomas, 12% are small-cell tumors, and 2% are large-cell 
tumors, whereas the remainder is other unspecified morphologies [1]. The diagnosis of 
NSCLC is typically based on morphological evaluations of biopsy or surgical specimens 
[3,6]. In SCLC, the diagnosis is mainly based on nuclear characteristics of a cytological 
sample [7]. 
Current healthcare administrative data represent a valuable source of information 
for Real-World-Evidence planning resources allocation and carrying out population stud-
ies [8]. The ICD 9th Revision, Clinical Modification (ICD-9-CM) codes in the Hospital Dis-
charge Records, outpatient procedures codes, and the Anatomical Therapeutic Chemical 
(ATC) classification of medications are widely used to select study cohorts [9]. However, 
these data sources lack sufficient granularity for specific subpopulation studies. Such lim-
itation is apparent in subpopulation studies on lung cancer, for which, for example, there 
is not an ICD-9-CM code specific for non-small-cell lung cancer and small-cell lung cancer 
diagnosis [10]. 
So far, no Italian studies have been published reporting the accuracy of using admin-
istrative data to identify NSCLC and SCLC cases. However, some experiences assessing 
the validity of ICD-9-CM codes for lung cancer have been reported [9]. Several studies 
have been published in other countries, especially in US, where claims data, being primar-
ily used for reimbursement purposes, are detailed and reliable. In a 2009 study, Ramsey 
et al. [11] estimated an accuracy of 51.1% in identifying incident NSCLC cases from ad-
ministrative data using only ICD-9-CM codes. 
Duh et al. [12] developed an algorithm to identify SCLC cases based on the treatment 
guidelines of the American Cancer Society and the National Comprehensive Cancer Net-
work. The algorithm initially aimed to identify patients with SCLC; a modified version 
was subsequently proposed for identifying patients with NSCLC. In the latter algorithm, 
procedures and chemotherapies for patients with NSCLC are employed as inclusion cri-
teria, while the exclusion criteria consist of chemotherapy regimens administered to pa-
tients with SCLC [12–14]. A recent validation of the algorithm estimated an accuracy of 
92.1% with a sensitivity of 94.8% and a specificity of 81.1% [13]. 
More recently, reporting the results of the VALIDATE-J study, de Louise et al. [14] 
demonstrated high specificity and positive predictive value for claims-based algorithms 
in identifying both incident and prevalent lung cancers cases using Japanese claims data. 
However, the authors did not provide any consideration on differentiating SCLC and 
NSCLC. 
Within the available literature in Europe, worthy of note is an incidence study carried 
out to estimate the cost of NSCLC treatment in France, Germany, and the United Kingdom 
[10]. In this study, patients diagnosed with NSCLC were identified from hospital dis-
charge records, outpatient visits, pharmaceutical services; however, a validation of the 
procedure is lacking. This study was aimed at defining a validated procedure to estimate 
the incidence and prevalence of NSCLC and SCLC from healthcare administrative data-
bases generated in routine care in a region of northwest Italy of about 43,000,000 residents 
[15] with 3450 incident cases in 2018 [16]. External validation of the results is also provided 
by assessing the accuracy, sensitivity, specificity, and the predictive values of the method 
on a clinical cohort of patients available at the Romagnolo Scientific Institute for the Study 
and Treatment of Tumours, in the region of Emilia Romagna, Italy. 
2. Materials and Methods 
2.1. Data 
The study population included all residents in Piedmont, a northwestern region of 
Italy, during 2013–2017. Data were drawn from the Piedmont Health Information System, 
including the Hospital Discharge Registry, Drugs Prescriptions Registry, and Outpatient 
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Registry. Cases of lung cancer were retrieved from the Regional Hospital Discharge Reg-
istry, according to the ICD-9-CM. Data on vital status were also obtained from the regional 
mortality registry. 
A cohort of incident cases and a second cohort of prevalent cases were retrieved. To 
identify incident cases, we selected the records of patients with diagnosis of lung cancer 
between 1 January 2017 and 31 December 2017 using ICD-9-CM codes 162.X and 213.2 
located in the primary position of the Hospital Discharge Registry; prevalent cases, i.e., 
patients with the same diagnosis (ICD-9-CM codes 162.X in any position) between 2013 
and 2016 were excluded. The second cohort of prevalent cases was selected using ICD-9-
CM diagnostic codes (162.X) in any position between 2013 and 2017. 
The selected records were linked to the Drugs Prescriptions Registry and the Outpa-
tient Registry. 
From the Drugs Prescriptions Registry, records with the chemotherapy treatments 
listed in Table 1 were retrieved. 
Table 1. ATC codes of the drugs in the first line of treatment of NSCLC and SCLC according to the 
Italian Association of Medical Oncology Guidelines [17]. 
NSCLC SCLC 
Drug ATC Code Drug ATC Code 
Crizotinib L01XE16 Etoposide L01CB01 
Aletinib L01XE36 Topotecan L01XX17 
Ceritinib L01XE44 Carboplatin L01XA02 
Osimertinib L01XE35 Cisplatin L01XA01 
Gefitinib L01XE02   
Erlotinib L01XE03   
Afatinib L01XE13   
Nivolumab L01XC17   
Pembrolizumab L01XC18   
Bevacizumab L01XC07   
Irinotecan L01XX19   
Atezolizumab L01XC32   
Durvalumab L01XC28   
Platinum-based chemotherapy L01XA   
ATC = Anatomical Therapeutic Chemical; NSCLC = non-small-cell lung cancer; SCLC = small-cell 
carcinoma. 
From the Outpatient Registry, information on radiotherapy, chemotherapy, and di-
agnostic procedures listed in Table 2 were retrieved. From the Hospital Discharge Regis-
try, radiotherapy and chemotherapy procedures received were retrieving from ICD-9-CM 
procedure codes in any position (Table 3).  
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Table 2. Procedures for radiotherapy and chemotherapy treatment considered for NSCLC/SCLC lung cancer characteri-
zation selected from the Outpatients Registry. 
Procedure Description Radiotherapy Treatment Chemotherapy Treatment 
Head CT with and without contrast   
Thoracic CT   
Thoracic CT with and without contrast   
Upper abdomen CT   
Upper abdomen CT with and without contrast   
Complete abdominal CT   
Complete abdominal CT with and without contrast   
MRI Brain and encephalic trunk   
MRI brain and encephalic trunk with and without contrast   
PET (quantitative)   
Total body PET   
Telecobalt therapy multiple fields, moving X  
Teletherapy with linear accelerator with multiple fields or movement for 3D 
technique 
X  
Teletherapy with linear accelerator with multiple fields or movement with 
modulation of intensity 
X  
Teletherapy with linear accelerator fixed field X  
Teletherapy with linear accelerator with multiple fields, moving X  
Teletherapy with linear accelerator flash technique X  
Radiotherapy with linear accelerator with MLC for IMRT static or dynamic 
multiple fields or moving 
X  
Electron beam teletherapy with one or more fixed fields X  
Total skin electron irradiation (TSEI/TSEBI) X  
Injection or infusion of chemotherapy for tumor  X 
Antitumoral therapy with infusion of drug  X 
Antitumoral therapy with oral drugs or IM or subcutaneous injection  X 
CT = Computer Tomography; PET = Positron Emission Tomography; IMRT = Intensity Modulated Radiotherapy; MLC = 
Multileaf Collimator; TSEI = Total Skin Electron Irradiation; TSEBI = Total Skin Electron Beam Irradiation; IM = Intramus-
cular. 
Table 3. Procedure on respiratory system and radiotherapy treatment for NSCLC/SCLC lung cancer characterization to 
select from the Hospital Discharge Registry. 
Procedure Code Procedure Description Procedure on Respiratory System Radiotherapy Treatment 
32 
32.0–32.9 
Excision of lung and bronchus X  
33 
33.0–33.9 
Other operations on lung and bronchus X  
34 
34.0–34.9 
Operations on the chest wall, pleura, mediastinum, and 
diaphragm 
X  
92.21 Superficial radiation  X 
92.22 Orthovoltage radiation  X 
92.23 Radioisotopic teleradiotherapy  X 
92.24 Teleradiotherapy using photons  X 
92.25 Teleradiotherapy using electrons  X 
92.26 Teleradiotherapy of other particulate radiation  X 
92.27 Implantation or insertion of radioactive elements  X 
92.28 Injection or instillation of radioisotopes  X 
92.29 Other radiotherapeutic procedure  X 
92.30 Stereotactic radiosurgery, not otherwise specified   X 
92.31 Single source photon radiosurgery  X 
92.32 Multi-source photon radiosurgery  X 
92.33 Particulate radiosurgery  X 
92.39 Stereotactic radiosurgery, not elsewhere classified  X 
2.2. Statistical Analysis 
NSCLC/SCLC classification of lung cancer histological type was performed using a 
latent class statistical model. Latent class analysis is a multivariate categorical data analy-
sis technique that identifies and characterizes clusters of observations sharing a similar 
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distribution of the variables of interest [18]. Latent class models attempt to stratify obser-
vations based on variables (manifest variables) crossed with an unobserved outcome (la-
tent variable). Such models probabilistically assign each observation to a latent class based 
on the observed values of the manifest variables. 
The following manifest variables were considered: (i) the type of chemotherapy treat-
ment (since potentially, each patient has more than one chemotherapy treatment, the two 
most recent treatments were picked up) identified on the basis of the codes shown in Table 
1; (ii) outpatient procedures listed in Table 2; (iii) having had a procedure among those 
listed in Table 3 (interventions on the respiratory system column); (iv) having undergone 
a radiotherapy treatment (Tables 2 and 3). 
Since the unobserved latent variable (the histological type NSCLC/SCLC) is a nomi-
nal variable, the latent class model is a finite mixture model. 
Each of the 4 manifest variables considered has 𝑘  𝑚 = 1, … ,4  categories. Let 𝑌  
be the observed 𝑚 − 𝑡ℎ manifest variable on the 𝑖 − 𝑡ℎ subject such that 𝑌 =  1 if the 𝑖 − 𝑡ℎ patient has the category 𝑘 and 0 otherwise. For example, if the manifest variable 
is the type of chemotherapy treatment (𝑚 =  1), the categories are 16 (i.e., the number of 
the ATC codes in Table 1) and therefore, 𝑘 takes integer values between 1 and 16. Thus, 𝑘 =  2, 𝑌 = 1 if the i-th patient has taken the drug L01XE36 (the order in which the 
chemotherapy treatments are considered is irrelevant) and 0 otherwise. 
The latent class model approximates the joint distribution of the manifest variables 
as the weighted sum of a fixed number R of mixture components. The number R, which 
is the number of latent classes, is selected a priori, and it can be determined based on 
theoretical considerations or based on the goodness-of-fit indices of the model. In our case, 
we set two latent classes based on the classification problem of dividing the lung cancer 
population into NSCLC and SCLC. Then, we evaluated the consistency of this assumption 
with the calculation of the Akaike Information Criterion (AIC) [19]. 
Let 𝜋  be the conditional probability that a patient in the latent class 𝑟 (with 𝑟 = 
1, 2) has the 𝑘 − 𝑡ℎ value on the 𝑗 − 𝑡ℎ variable and let 𝑝  be the unconditional probabil-
ity that a patient belongs to the 𝑟 − 𝑡ℎ class before observing the manifest variables, i.e., 
the a priori probability latent class membership. Assuming the conditional independence 
between the manifest variables and the latent class, 
𝑃 𝑌 | 𝜋, 𝑝 = 𝑝 𝜋    (1)
where 𝑌  represents the probability density function of the manifest variables across all 
latent classes, and 𝑝  and 𝜋  are the model parameters that needed to be estimated. 
Given the estimates of the model parameters, the posterior probability that each patient 
belongs to each class, given the evidence of treatment and outpatients procedures, can be 
computed using Bayes’ formula. 
The model parameters were estimated using the Expectation–Maximization (EM) al-
gorithm [20]. The EM algorithm was chosen due to the iterative nature of the algorithm 
itself, which allows estimating the parameters of the model even in the presence of miss-
ing observations. In this case, in fact, the a priori probabilities are updated at each iteration 
using only the manifest variables for which observations are available 
All analyses were conducted with R version 4.0.2 (R Core Team, Vienna, Austria) 
[21]. 
3. Results 
In Table 4, the description of the cohort of patients with a diagnosis of lung cancer 
between 2013 and 2017 is reported stratified for vital status at the end of 2017. 
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Table 4. Description of the cohort of patients with diagnosis of lung cancer in 2013–2017. 
Variable 
Alive at 31/12/2017 Dead at 31/12/2017 Total 
N = 8721 N = 22,706 N = 31,427 
Sex, N (%)    
Females 2894 (33.2%) 6202 (27.3%) 9096 (.28.9%) 
Males 5827 (66.8%) 16,504 (72.7%) 22,331 (71.1%) 
Age, average (SD) 68.4 (10.4) 70.3 (10.5) 69.7 (10.5) 
The number of incident cases in 2017 is 3472. 
Overall, 2694 (77.6%) subjects underwent chemotherapy. 
The interventions on the respiratory system listed in Table 3 were reported on the 
Hospital Discharge Registry for 1818 (52.4%) patients. 
Finally, the 3472 incident cases were associated with 35,729 outpatient procedures, 
whose codes are listed in Table 2. 
The number of prevalent cases in the years 2013–2017 was 5820. Overall, 4824 (82.9%) 
of them were chemotherapy. 
3.1. Latent Class Analysis 
To estimate the size of the two subpopulations (NSCLC and SCLC cases), a model 
with two latent classes was applied, both to the incident and prevalent cases, considering 
the following manifest variables: (i) the type of chemotherapy treatment (since potentially, 
each patient has more than one chemotherapy treatment, the two most recent treatments 
were considered) among those shown in Table 1; (ii) the outpatient procedures that pa-
tients underwent among those listed in Table 2; (iii) having had a procedure among those 
listed in Table 3 (column Interventions on the respiratory system); (iv) having undergone 
a radiotherapy treatment among those listed in Table 2 of the outpatients procedures and 
Table 3 (column Radiotherapy treatment). 
Based on the AIC, which measures the goodness of fit of the data (the smaller the 
value, the better the model), the model without radiotherapy treatment is to be preferred 
in estimating the size of the two subpopulations, both for the incident and prevalent cases. 
Regarding the incident cases, two latent classes comprising 15.2% and 84.8% of cases 
were identified (SE ± 1.1%) (Table 5). By examining the unconditional probabilities re-
ported in Supplementary Table S1 for incident cases, the two subpopulations were as-
signed the type of lung cancer (NSCLC or SCLC). In fact, observing the ATC codes, class 
1 mainly consists of patients treated with Etoposide (L01CB01, 33%), Carboplatin 
(L01XA02, 38%), Cisplatin (L01XA02, 23%), and residually with Topotecan (L01XX17). 
Moreover, class 1 also has a greater likelihood of outpatient procedures. Thus, SCLC cases 
were assigned to class 1 (15.2% of cases), whereas NSCLC cases were assigned to class 2 
(84.8% of cases). For the prevalent cases, two classes comprising 10.9% and 89.1% of cases 
were identified (SE ±1.1%) (Table 5). Following the same reasoning as for the incident 
cases, SCLC cases were assigned to class 1 (10.9% of cases), whereas NSCLC cases were 
assigned to class 2 (89.1% of cases).  
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Table 5. Proportion of NSCLC and SCLC lung cancer cases estimated by the latent class model. 
Latent Class Model NSCLC, % (SE) SCLC, % (SE) AIC 
Incident cases    
Model without information on radiotherapy 
treatment 84.8% (1.1%) 15.2% (1.1%) 12,292.81 
Model with information on radiotherapy 
treatment 82.9% (1.4%) 17.1% (1.4%) 14,381.76 
Prevalent cases    
Model without information on radiotherapy 
treatment 
89.1% (1%) 10.9% (1%) 18,211.88 
Model with information on radiotherapy 
treatment 80.2% (1.2%) 19.7% (1.2%) 21,131.83 
SE = standard error. 
3.2. External Validation 
A first validation of the estimate of the size of the two subpopulations of patients 
with lung cancer (NSCLC and SCLC) was made by comparing the results obtained with 
the estimates reported in the literature. The most recent publication in which data are re-
ported is the work of Mazzanti et al. [22], who cites the data in Carrato et al. [23] and 
Herbst et al. [24], for which the cases of NSCLC account for approximately 85% of lung 
cancers. As for the Italian population, the incidence figure of lung cancer is not presented 
stratified in the two forms NSCLC and SCLC [1]. 
The data from the Piedmont Region Cancer Registry reported 3450 incident cases in 
2018, which was comparable with the data that was extracted from the administrative 
databases of 3472 incident cases in 2017 [25]. 
The most recent data available with cytohistological confirmation are those relating 
to the period 2008–2012 [19]. Cytohistological confirmation is present in about three-quar-
ters of the series, and 12% of these are small cell tumors. These data are also compatible 
with the estimate of the prevalent cases (Table 5) equal to 10.9% (SE = 1%). 
A cohort of 107 individuals resident in Emilia Romagna diagnosed with lung cancer 
at the Romagnolo Scientific Institute for the Study and Treatment of Tumours, in the re-
gion of Emilia Romagna (Italy), for whom cytohistological confirmation was available, 
was used as the gold standard to assess the sensitivity, specificity, and predictive values 
of the method developed. Overall, 87 out of 107 presented NSCLC. The model developed 
assigned to each patient a probability of membership to the latent class NSCLC or SCLC. 
Thus, the patients were assigned to the most likely (higher probability of membership) 
latent class. 
Comparing the classification provided by the model with the gold standard, the over-
all accuracy was 95.3%, 95% Confidence Interval (95%CI): 89.4–98.5% (102 patients out of 
107 correctly classified); the sensitivity was 95.6% (95%CI: 89–98.8%), and the specificity 
was 94.1% (95%CI: 71.3–99.9%). Finally, positive and negative predictive values were 
98.9% (95%CI: 92.8–99.8%) and 80% (95%CI: 60.1–91.3%), respectively. 
4. Discussion 
To estimate the proportion of NSCLC and SCLC cases, we analyzed a cohort of inci-
dent cases of lung cancer between the years 2013 and 2017 in a region of northern Italy, 
and we applied a latent class analysis. The same analysis was repeated on the prevalent 
cases. 
Overall, a proportion of NSCLC diagnoses was estimated to be 85% of the total num-
ber of lung cancer on the cohort of incident cases and 89% on the cohort of prevalent cases. 
Int. J. Environ. Res. Public Health 2021, 18, 9076 8 of 10 
 
 
The estimate was obtained using a model with two latent classes, thus neglecting a 
potential 5% (according to estimates reported in the literature) of cases not classified nei-
ther as NSCLC nor SCLC histotype. 
The radiotherapy treatment seems not to increase the information needed to discrim-
inate between the two types of cancer. Improving the temporal setting of analysis of 
chemo or radiotherapy procedures (for example, by identifying the first, second, and third 
lines of treatment) would probably increase the discriminating power of such information. 
Finally, we conducted an external validation of the model results in two steps. First, 
we compared the data obtained with the data published by the Piedmont Cancer Registry 
and published. The data from the Piedmont Region Cancer Registry confirmed 3450 inci-
dent cases in 2018, which is comparable with the 3472 cases in 2017 we retrieved from the 
healthcare administrative databases, showing a reliable selection of the cohort. A major 
limitation is given on the availability of data with cytohistological confirmation, which is 
currently available only on about 75% of cases diagnosed between 2008 and 2012. Never-
theless, 12% of these cases are confirmed SCLC cases, which is compatible with the esti-
mate of the prevalent cases (Table 5) equal to 10.9% (SE ± 1%). 
Second, we conducted a validation on a cohort of patients diagnosed with lung can-
cer, at the Romagnolo Scientific Institute for the Study and Treatment of Tumours, in the 
region of Emilia Romagna (thus on patients who are not resident in Piedmont), for whom 
information on the histological type was available. This external validation confirmed a 
high sensitivity (95.6%), specificity (94.1%), and predictive values (99.9% and 80% as PPV 
and NPV, respectively). However, a major limitation relies on the size of the cohort of 
patients available, which was of 107 patients. 
5. Conclusions 
To our knowledge, this is the first Italian study on a validated procedure aimed at 
identifying cases of NSCLC and SCLC diagnosis from healthcare routinely collected data.  
Our validation based on a gold standard of 107 patients with diagnosis of lung cancer 
and histological confirmation showed 95% of accuracy, high sensitivity (95.6%), and spec-
ificity (94.1%). 
Even if the validation was performed on a gold standard of only 107 patients, the 
operative characteristics of our procedure are comparable with those of the algorithm in-
itially developed by Duh et al. [12] on a claims database, which achieved an accuracy of 
92.1% with a sensitivity of 94.8% and a specificity of 81.1% [13]. 
The developed procedure is a promising easy-to-use tool to design subpopulation 
studies on lung cancer for risk stratification or for better planning resource allocation. The 
latter issue is crucial, since the characterization of the histologic type plays an increasingly 
pivotal role in the multidisciplinary approach in the diagnosis and management of lung 
carcinoma [4]. 
Supplementary Materials: The following are available online at www.mdpi.com/1660-
4601/18/17/9076/s1, Table S1: Conditional probabilities of ATC code, outpatient procedures, and in-
tervention respiratory system stratified by class on incident cases (without radiotherapy treatment). 
SCLC type was assigned to class 1; NSCLC type was assigned to class 2. 
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